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Upregulation of hepatic bile acid synthesis
via fibroblast growth factor 19 is defective
in gallstone disease but functional
in overweight individuals
Olga Renner1, Simone Harsch1, Silke Matysik2, Dieter Lu¨tjohann3,
Gerd Schmitz2 and Eduard F Stange4
Abstract
Background: Fibroblast growth factor 19 (FGF19) is an enteric hormone regulating bile acid de novo synthesis by sensing
ileal bile acid flux. However, the role of FGF19 in cholelithiasis has not yet been elucidated and therefore is investigated in
the present study.
Methods: Total mRNA and protein were isolated from ileal biopsies and used for tissue expression analysis. FGF19,
7a-hydroxycholesterol (7a-OH-Chol), 27-hydroxycholesterol (27-OH-Chol), and different bile acids were determined in the
blood samples.
Results: FGF19 serum levels did not differ between gallstone carriers and controls but were significantly decreased in the
overweight individuals (32%, p¼ 0.0002), irrespective of gallstone status (normalweight to overweight controls 29%,
p¼ 0.0017; normalweight to overweight gallstone carriers 44%, p¼ 0.0338), and correlated inversely with bodyweight
(p< 0.0001, r¼0.3317). Compared to non-overweight controls, apical sodium-dependent bile acid transporter expression
was significantly diminished in the non-overweight gallstone carriers (42%, PmRNA¼ 0.0393; 52%, pprotein¼ 0.0169) as
well as in the overweight controls (24%, PmRNA¼0.0148; 43%, pprotein¼ 0.0017). FGF19 expression varied widely and was
similar in all groups. A significant negative correlation was noted between 7a-OH-Chol, 27-OH-Chol, and FGF19 serum
levels (p< 0.01; r7a-OH-Chol¼0.2155; r27-OH-Chol¼0.2144) in obesity.
Conclusion: Upregulation of hepatic bile acid synthesis via FGF 19 is defective in gallstone disease but functional in
overweight individuals.
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Introduction
Fibroblast growth factor 19 (FGF19) is a humoral
factor with several regulatory functions including
metabolic rate,1 bile acid homeostasis,2 and gallblad-
der ﬁlling.3 FGF19 transcripts are found in the small
intestine, brain, cartilage, skin, retina, and gall blad-
der but very low in the normal liver.4,5 Initial inter-
est in FGF19 as a metabolic regulator was prompted
by the phenotype of FGF15 (the mouse homologue
of FGF19) of transgenic mice where decreased obes-
ity, increased energy expenditure, reduced liver
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triglycerides, elevated fatty acid oxidation, and
improved insulin sensitivity were observed.1
Administration of human recombinant FGF19
increased the metabolic rate and reversed dietary
and leptin-deﬁcient diabetes in mice.6 Besides con-
trolling gall bladder reﬁlling by relaxation of gall
bladder smooth muscle,3 FGF19 is also a key
player involved in the regulation of bile acid homeo-
stasis.7 Using genetically modiﬁed mice it was shown
that intestinal farnesoid X receptor (FXR)/FGF15
has a predominant role in the inhibition of bile
acid biosynthesis.8 Intestinal FGF19 expression is
stimulated by bile acid mediated activation of FXR
and the enterokine is secreted into the enterohepatic
circulation. In addition to FXR, intestinal expression
of FGF19 is regulated by several nuclear receptors
such as pregnane X receptor (PXR) together with its
heterodimer partner retinoid X receptor (RXR).9,10
In the liver, a stabilizing cofactor bKlotho is neces-
sary for binding of FGF19 to its hepatic receptor
ﬁbroblast growth factor receptor 4 (FGFR4), creat-
ing a complex signalling through the c-Jun kinase
cascade,4 ultimately leading to suppression of chol-
esterol 7 alpha-hydroxylase/cytochrome P450 7A1
(CYP7A1) expression.2 Circulating FGF19 exhibits
a diurnal rhythm controlled by transintestinal bile
acid ﬂux.11 Diminished serum FGF19 and increased
bile acid synthesis were found in patients character-
ized by intestinal bile acid malabsorption (primary
(idiopathic) bile acid malabsorption, inﬂammatory
bowel disease, or ileal resection).12,13 Fasting
FGF19 levels were shown to exhibit diﬀerences
between cases and controls in patients with choles-
tasis,14 obesity,15 and bile acid diarrhoea.16
In spite of its important role in energy and bile acid
metabolism, the function of FGF19 in gallstone disease
has not been studied. In non-overweight gallstone dis-
ease bile acid synthesis was paradoxically unchanged
despite a reduction of the bile acid pool size and an
increased fractional turnover.17,18 The latter may be
related to the impaired absorption of bile acids in gall-
stone disease.19 Most likely, the molecular basis of bile
acid malabsorption in gallstone disease is the dimin-
ished ileal expression of apical sodium-dependent bile
acid transporter (ASBT), ileal lipid binding protein
(ILBP), and organic solute transporter alpha/beta
(OSTa/b).20,21
The lack of induction of hepatic bile acid synthe-
sis regardless of ileal loss may be a consequence of
defective FGF19 response in the ileum. In the pre-
sent study, we therefore analysed serum levels and
ileal expression of FGF19 as well as bile acid metab-
olite levels, ileal bile acid transporters, and relevant
transcription factors in a cohort of gallstone carriers
and controls.
Patients and methods
Ethics statement
Informed consent was obtained from each patient
included in the study and the study protocol conﬁrms
to the ethical guidelines of the 1975 Declaration of
Helsinki as reﬂected in a priori approval by the institu-
tion’s human research committee (ethics committee of
the University Hospital of Tuebingen and University of
Tuebingen).
Subjects and materials
The selection as well as including and excluding criteria
of study subjects were applied as previously described22
and characteristics of the analysed cohort are summar-
ized in Supplementary Table S1 (available online). Ileal
mucosal forceps biopsies and fasting blood samples
were collected during routine colonoscopy from a
total of 168 individuals, comprising 134 healthy con-
trols and 34 individuals with asymptomatic gallstones.
As weight also depends on age23–27 and the mean age
was over 50 years in the analysed cohort, the normal-
weight group was deﬁned as body mass index (BMI)
25.4 kg/m2 (as a mathematical value of 25) and
individuals with BMI >25.4 kg/m2 were regarded as
overweight.
For tissue gene expression analysis in an ileal muco-
sal biopsy, total mRNA and protein were isolated using
TRIzol Reagent (Invitrogen) according to the manufac-
turer’s protocol. The quality and quantity controls of
isolated material were assessed as reported.22 Blood
samples (3–5ml) were used for determination of total
serum cholesterol and triglyceride levels as well as for
bile acid metabolism proﬁling (measurements of bile
acid synthesis markers, serum bile acid, and FGF19
concentrations). Serum triglycerides and cholesterol
levels were analysed by standard clinical tests.
Determination of serum FGF19
FGF19 levels were determined using a sandwich
ELISA kit (BioVendor, Czech Republic). All cooled
serum samples were diluted 1:3 and analysed following
the manufacturer’s instructions.
Real-time quantitative reverse-transcription PCR
RT-PCR was performed with LightCycler sequence
detection system (Roche Diagnostics) as reported pre-
viously.21,22,28 Primer sequences used for ampliﬁcations
and speciﬁc PCR conditions are listed in
Supplementary Table S2. At the end of the cycling pro-
gram, a dissociation curve was calculated. The quantity
for any given transcript was calculated using the second
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derivative maximum method. Gene-speciﬁc plasmid
constructs were generated as reported previously21,29
and served as positive control templates. All measure-
ments were carried out in duplicate.
Western blot analysis
The antibody used for the detection of human ASBT
protein was a kind gift of Prof P Dawson (Wake Forest
University, Winston-Salem, USA). Protein determin-
ation was performed as previously described.28
Measurement of bile acid synthesis markers
Sample preparation for determination of 7a-hydroxy-
cholesterol (7a-OH-Chol) and 27-hydroxycholesterol
(27-OH-Chol) as well as consecutive measurement by
GC-MS was performed as previously described30
with slight modiﬁcations. Details are described in the
supplementary ﬁle.
Measurement of bile acids in plasma
Sample preparation and methodology for bile acid LC-
MS/MS analysis is described elsewhere.31 Fifteen
bile acid species were quantiﬁed: cholic acid (CA), che-
nodeoxycholic acid (CDCA), deoxycholic acid
(DCA), lithocholic acid (LCA), ursodeoxycholic acid
(UDCA), and their glycine (G) and taurine (T) conju-
gated derivates.
Statistics
For statistical analysis GraphPad Prism 5 was used
(GraphPad Software, San Diego, CA, USA). Clinical
characteristics of study participants and all data are
presented as mean standard error of the mean.
Diﬀerences between groups were investigated using
the Mann–Whitney U-test. All correlations between
variables were analysed with Spearman’s rank test.
All statistical tests were two-tailed and a p-value
<0.05 was considered as statistically signiﬁcant.
Results
Serum FGF19
In the total population, there was no diﬀerence between
serum FGF19 concentration in gallstone carriers and
controls (p¼ 0.4000; Figure 1A). Notably, fasting
FGF19 serum levels exhibited a signiﬁcant reduction
by 32% in overweight individuals (p¼ 0.0002;
Figure 1B). Also after stratiﬁcation into weight-speciﬁc
subgroups, FGF19 plasma concentrations were com-
parable between gallstone subjects and controls
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Figure 1. Circulating levels of FGF19 in gallstone patients and
controls in overnight fasting individuals according to presence
of gallstone (A), weight (B), and presence of gallstone with
weight (C).
Values are mean SEM. Mann–Whitney U-test, p< 0.05. BMI,
body mass index; C, control; GS, gallstone carrier; NW, normal-
weight; OW, overweight. (A) C, n¼ 129; GS, n¼ 333. (B) NW,
BMI 25 kg/m2, n¼ 81; OW, BMI> 25 kg/m2, n¼ 81. (C) NW: C,
n¼ 70, GS, n¼ 11; OW: C, n¼ 59, GS, n¼ 22.
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(Figure 1C) both in the normalweight and the over-
weight groups. However, overweight persons exhibited
signiﬁcantly lower FGF19 serum levels than non-over-
weight individuals independent of gallstone status (nor-
malweight to overweight controls 29%, p¼ 0.0017;
normalweight to overweight gallstone carriers 44%,
p¼ 0.0338). Moreover, FGF19 plasma levels correlated
inversely with BMI (p< 0.0001 r¼0.3317). FGF19
serum levels were similar between overweight
(BMI> 25.4 kg/m2) and obese (BMI> 30 kg/m2) indi-
viduals (data not shown).
Ileal expression of FGF19, bile acid transporters,
and relevant transcription factors
Overall, there was no signiﬁcant diﬀerence in FGF19
expression between gallstone carriers and controls
(Figure 2A). As in previous investigations,32 the wide
interindividual variations of basal FGF19 mRNA
expression rendered statistical comparisons diﬃcult.
Next, the expression of ileal bile acid transporters
was quantiﬁed. In essence, we conﬁrmed our prior ﬁnd-
ing of diminished bile acid transporters expression in
the intestine of female gallstone patients,20,21 now irre-
spective of gender in a composite cohort of female and
male gallstone carriers. The expression of all intestinal
bile acid transporters was distinctly reduced in non-
overweight gallstone carriers (ASBT 42%,
p¼ 0.0393, Figure 2B; ILBP 74%, p¼ 0.0046,
Figure 2C; OSTa 34% p¼ 0.1023, Figure 2D; OSTb
52% p¼ 0.0378, Figure 2H). Remarkably, overweight
subjects exhibited diminished bile acid transporter
levels in comparison with non-overweight controls
(ASBT 24%, p¼ 0.0148; ILBP 47%, p¼ 0.0449;
OSTa 21%, p¼ 0.0852; OSTb 22%, p¼ 0.2342).
At the protein level, ASBT expression was reduced by
52% in non-overweight gallstone carriers compared
to controls (p¼ 0.0169) and by 43% in overweight
control individuals compared to normalweight controls
(p¼ 0.0017). The intestinal expression of the ASBT
transporter on protein levels did not diﬀer between
overweight controls and the gallstone group
(p¼ 0.7517; Supplementary Figure S1).
There were signiﬁcant positive correlation coeﬃ-
cients between the transporters (ASBT/ILBP r¼ 0.72,
ASBT/OSTa r¼ 0.71, ASBT/OSTb r¼ 0.68, ILBP/
OSTa r¼ 0.82, ILBP/OSTb r¼ 0.70, OSTa/OSTb
r¼ 0.77; n¼ 117, p< 0.0001). In contrast, the correl-
ation coeﬃcients for intestinal FGF19 mRNA expres-
sion and bile acid transporters were low (ASBT
r¼ 0.22, p¼ 0.0153; ILBP r¼ 0.44, p< 0.0001; OSTa
r¼ 0.41, p< 0.0001; OSTb r¼ 0.35, p¼ 0.0002). FXR,
PXR, and RXR mRNA expression does not diﬀer sig-
niﬁcantly between gallstone carriers and controls
(Figure 2E–G). No correlation was found between
intestinal FXR and FGF19 expression (r¼ 0.03, ns).
There was moderate association between mRNA expres-
sion of FGF19, PXR, and RXR (FGF19/PXR r¼ 0.35,
p< 0.0001; FGF19/RXR r¼ 0.23, p¼ 0.0156).
Markers of bile acid synthesis
Furthermore, markers of hepatic neutral/classic (7a-
OH-Chol) and acidic/alternative (27-OH-Chol) bile
acid synthesis pathways were analysed and displayed
as ratio of oxysterol to plasma total cholesterol level
(Figure 3). In line with observations from serum
FGF19 levels, both markers of bile acid synthesis
were comparable between controls and gallstone car-
riers in the total group (Figure 3A and B), but signiﬁ-
cantly increased in overweight individuals irrespective
of gallstones (7a-OH-Chol þ20%, p¼ 0.0055; 27-OH-
Chol þ12%, p¼ 0.0403; Figure 3C and D). Moreover,
levels of the bile acid precursors were not signiﬁcantly
diﬀerent between gallstone carriers and controls in
the weight-speciﬁc subgroups (Figure 3E and F).
Therefore, 7a-OH-Chol- and 27-OH-Chol-mediated
bile acid synthesis ratios were higher in overweight indi-
viduals than in normalweight persons (þ19%
p¼ 0.0093; þ12% p¼ 0.0806). Besides, intermediates
of bile acid synthesis correlated inversely with serum
FGF19 levels (7a-OH-Chol r¼0.2155, p< 0.01; 27-
OH-Chol r¼0.2144, p< 0.01). Finally, ileal bile acid
transporter as well as FGF19 expression and the mar-
kers of hepatic de novo bile acid synthesis revealed no
signiﬁcant association (data not shown).
Plasma bile acid concentrations
To investigate the inﬂuence of reduced bile acid
reabsorption in the intestine on serum levels, the con-
centrations of diﬀerent bile acids were measured. As
shown in Figure 4, the total amount of bile acids in
plasma is signiﬁcantly diminished (74%, p¼ 0.0374)
in non-overweight gallstone carriers compared to rele-
vant controls. This reduction was most pronounced for
primary bile acids in plasma (75%, p¼ 0.0334), sec-
ondary bile acids in serum of normalweight gallstone
carriers were not signiﬁcantly reduced. In overweight
gallstone carriers, the total bile acid concentration
was lower by about 33% compared to overweight
controls, but this eﬀect also did not reach statistical
signiﬁcance (p¼ 0.6215). Notably, bile acid concentra-
tion in overweight persons was reduced up to 21%
compared to non-overweight healthy individuals
(p¼ 0.3235).
Table 1 shows the data of all analysed bile acid spe-
cies including their free form as well as glycine or taur-
ine conjugates. The calculated data exhibit the uniform
pattern of reduction for every bile acid type in the
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Figure 2. Ileal expression of FGF19 (A), apical sodium-dependent bile acid transporter (ASBT), (B), ileal lipid-binding protein (C), organic
solute transporter a (D), FXR (E), PXR (F), RXR (G), and organic solute transporter b (H) in gallstone patients and controls.
Quantification of mRNA was performed in human ileal mucosal biopsies of gallstone carriers and controls and is given as copy number.
All experiments were carried in duplicate. Values are mean SEM. Mann–Whitney U-test, p< 0.05. BMI, body mass index; C, control; GS,
gallstone carrier; NW, normalweight; OW, overweight. NW: C, n¼ 57; GS, n¼ 9; OW: C, n¼ 50, GS, n¼ 21.
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Figure 3. Circulating markers of the hepatic de novo bile acid synthesis in gallstone patients and controls according to presence of
gallstone (A, B), weight (C, D), and presence of gallstone with weight (E, F): 7a-hydroxycholesterol (A, C, E) and 27-hydroxycholesterol
(B, D, F).
Serum concentrations are ratio oxycholesterol (ng/ml)/cholesterol (mg/dl)*100. Values are mean SEM, Mann–Whitney U-test, p< 0.05.
BMI, body mass index; C, control; GS, gallstone carrier; NW, normalweight; OW, overweight. (A, B) C, n¼ 90; GS, n¼ 29. (C, D) NW,
BMI 25 kg/m2, n¼ 60; OW, BMI> 25 kg/m2, n¼ 59. (E, F) NW: C, n¼ 51, GS, n¼ 9; OW: C, n¼ 39, GS, n¼ 20.
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gallstone group. As reported by Matysik et al.,33 the
glycine-conjugated primary bile acid GCDCA repre-
sented the highest plasma level, followed by TCDCA
und CDCA. Remarkably, only TUDCA and CA were
increased (TUDCA þ20%, p¼ 0.4200; CA þ180%,
p¼ 0.5500) in overweight gallstone patients compared
with respective controls, but without signiﬁcance.
Discussion
In the present study, we examined the role of FGF19 in
gallstone disease and excess weight, determining its cir-
culating levels as well as ileal expression of FGF19,
relevant transcription factors, bile acid transporters,
and bile acid metabolite serum levels. The major
novel ﬁnding suggests that FGF19 expression as well
as concentrations in the blood do not adequately
respond to the diminished ileal bile acid reabsorption
in gallstone carriers and therefore fail to stimulate the
bile acid synthesis in the liver. The additional non-gall-
stone control group of overweight individuals, where
ileal bile acid reabsorption is also reduced and
FGF19 concentrations are declined as expected
(unlike gallstone patients), exactly showed the FGF19
response which would be expected in the case of ade-
quate upregulation of bile acid synthesis. Accordingly,
FGF19 levels are reduced and bile acid synthesis is
enhanced in the overweight but not in the gallstone
subjects.
The pathogenesis of gallstones is complex and is
related to a large number of risk factors such as obesity,
age, female gender, nutrition, and genetics. Most data
point to a diminished intestinal bile acid absorption as
well as pool size in gallstone patients,17,19 which should
prompt a compensatory increase in synthesis. However,
bile acid synthesis remains unaltered in non-overweight
gallstone patients.17,18 Also, we found unchanged bile
acid synthesis markers and remarkably a signiﬁcant
decrease of bile acids in plasma of normalweight gall-
stone carriers. Such a metabolic imbalance would
explain the enhanced cholesterol lithogenicity due to a
relative lack of bile acids in gallstone bile. This process
apparently depends on ethnicity, as paradoxically in
Hispanic gallstone carriers with unaltered ileal trans-
porter expression and faecal excretion of bile acids,
the level of CYP7A1 is increased.34 To further clarify
the factors involved in this dysregulation, we studied
the recently identiﬁed major regulator of bile acid syn-
thesis, FGF19.
Animal models provide evidence that stimulation of
FXR-mediated intestinal FGF15 expression suppresses
bile acid synthesis in the liver in a dominant way.7
Moreover, circulating intestinal FGF19 has a pro-
nounced diurnal variation and modulates bile acid syn-
thesis in men.11 Also in several diseases FGF19 is an
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Figure 4. Comparison of plasma bile acid concentrations in gall-
stone patients and controls according to presence of gallstone with
weight: total bile acids (A), primary bile acids (B), and secondary
bile acids (C).
Values are mean SEM, Mann–Whitney U-test, p< 0.05. BMI,
body mass index; C, control; GS, gallstone carrier; NW, normal-
weight; OW, overweight. NW: C, n¼ 74, GS, n¼ 11; OW: C, n¼ 59,
GS, n¼ 22.
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important regulator. For example, to prevent the accu-
mulation of toxic bile acids, the liver FGF19/FGFR4
signalling pathway was induced by the autocrine mech-
anism of bile acids35 and high FGF19 plasma levels as
well as increased FGF19 expression were detected in
the liver of patients with extrahepatic cholestasis as a
protective mechanism.14 Otherwise, reduced plasma
FGF19 levels were reported for patients with impaired
glucose tolerance, Type 2 diabetes mellitus and in bile
acid malabsorption, non-alcoholic fatty liver disease,
inﬂammatory bowel disease, or ileal resection and
were associated with increased bile acid synthe-
sis.12,13,15,36,37 Recently, in patients with idiopathic
bile acid-induced diarrhoea, FGF19 and 7a-hydroxy-
4-cholesten-3-one were shown to correlate negatively
and FGF19 was proposed to serve as diagnostic
marker for this disease.16 Furthermore, in diabetic
patients undergoing Roux-en-Y gastric bypass, lower
FGF19 levels were signiﬁcantly correlated with
increased hepatic expression of the CYP7A1 gene,
modulating bile acid production.38 In the present
study, diﬀerences in FGF19 levels and bile acid synthe-
sis markers were found between normal weight and
overweight individuals but remarkably not between
gallstone carriers and non-gallstone controls of similar
weight. In the additional control group of overweight
individuals, ileal bile acid reabsorption is reduced and
FGF19 concentrations declined as expected (unlike
gallstone patients).
As in prior studies,32 ileal FGF19 expression, which
is considered to be the source of FGF19 in the circula-
tion, varied widely and did not correlate with serum
levels (Supplementary Figure S2). These large inter-
individual diﬀerences in FGF19 expression are also
not explained by the expression of relevant transcrip-
tion factors (FXR, PXR, and RXR). In addition,
FGF19 levels may be aﬀected by sequence variations
in the gene, epigenetic as well as posttranslational fac-
tors, and variations in protein degradation. The lack of
change in bile acid synthesis markers is in accordance
with several studies. Moreover, the diminished ileal bile
acid transporter expression observed here conﬁrms our
previous reports,20,21 now in non-overweight male
patients (Supplementary Figure S3).
Cholesterol and bile acid synthesis are closely linked
but diﬀer among overweight and normalweight individ-
uals. Obesity is characterized by an excessive biliary
cholesterol, less increased bile acid secretion, and a
high lithogenic index.39 Bile acid synthesis is also ele-
vated40 and pool size is normal or enlarged in the
obese39,41 without evidence of bile acid malabsorp-
tion.42 There is a loose but positive correlation between
Table 1. Serum bile acid profile in gallstone patients and controls
Bile acid
type
Normalweight Overweight
Controls
(n¼ 74)
Gallstone
carriers
(n¼ 11)
Difference
(%) p-value
Controls
(n¼ 59)
Gallstone
carriers
(n¼ 23)
Difference
(%) p-value
Primary
TCA 0.200 0.044 0.021 0.006 90 0.017 0.174 0.038 0.101 0.033 42 0.47
GCA 0.444 0.080 0.073 0.021 84 0.017 0.375 0.074 0.258 0.077 31 0.47
CA 0.018 0.007 0.005 0.002 72 0.128 0.015 0.004 0.041 0.025 180 0.55
TCDCA 0.809 0.113 0.327 0.049 60 0.068 0.562 0.095 0.375 0.070 33 0.49
GCDCA 1.894 0.302 0.438 0.138 77 0.034 1.387 0.271 0.959 0.224 31 1.00
CDCA 0.243 0.050 0.042 0.008 83 0.010 0.214 0.040 0.162 0.040 24 0.42
Secondary
TDCA 0.122 0.019 0.023 0.009 81 0.042 0.127 0.035 0.069 0.030 46 0.66
GDCA 0.628 0.110 0.170 0.046 73 0.122 0.642 0.171 0.348 0.105 46 0.60
DCA 0.164 0.061 0.039 0.012 76 0.249 0.167 0.044 0.112 0.024 33 0.97
TLCA 0.010 0.001 0.008 0.004 20 0.400 0.011 0.003 0.009 0.003 16 0.80
GLCA 0.045 0.007 0.032 0.011 29 0.675 0.052 0.009 0.038 0.010 27 0.87
LCA 0.008 0.002 0.003 0.001 61 0.208 0.013 0.003 0.008 0.002 36 0.61
Tertiary
TUDCA 0.027 0.011 0.005 0.003 81 0.061 0.010 0.002 0.013 0.004 20 0.42
GUDCA 0.296 0.120 0.095 0.050 68 0.074 0.136 0.022 0.114 0.025 16 0.59
UDCA 0.037 0.006 0.005 0.003 87 0.001 0.038 0.007 0.025 0.006 36 0.32
Data are mean concentration (mmol/l) SEM., p-value obtained from a nonparametric two-tailed Mann–Whitney U-test. CA, cholic acid; CDCA, cheno-
deoxycholic acid; DCA, deoxycholic acid; G, glycine conjugates; LCA, lithocholic acid; T, taurine conjugates; UDCA, ursodeoxycholic acid.
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weight and bile acid formation43 and weight reduction
is associated with a reduction in biliary bile acid
output.39 Therefore, the elevated bile acid synthesis
contributes to the higher rates of cholesterol balance41
but is less than required to dissolve disproportionately
elevated cholesterol in bile.40 As FGF19 plays a central
role in the suppression of bile acid synthesis and secre-
tion,7 it was also suggested to participate in the regula-
tion of cholesterol, lipoprotein, triglyceride, and
glucose metabolism.1,6 In mice, high levels of FGF19
were related to low bodyweight1 which is in agreement
with previous data in humans15,44,45 and the observa-
tions in the present work.
In conclusion, bile acid transporter expression is low
in normalweight gallstone patients and overweight non-
gallstone controls, but adaptive upregulation of bile
acid synthesis through FGF19 is observed only in the
overweight non-gallstone group. This might explain bil-
iary lithogenesis in normalweight gallstone carriers
through lack of induction of bile acid synthesis to
balance intestinal bile acid loss.
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